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Introduction: Comparisons between regulatory authorities of similar size and regulatory
characteristics facilitate value-added benchmarking and provide insight into regulatory
performance. Such comparisons highlight areas for improvement as authorities move
toward achieving their regulatory goals and stakeholders’ demands. The aims of this
study were to compare the registration process and the regulatory review model
of the South African Medicines Control Council (MCC) to that of four other similar-
sized regulatory authorities and to identify areas for improvement that may inform
recommendations to the South African Health Products Regulatory Authority (SAHPRA)
as it looks to re-engineer and enhance the registration process in South Africa.
Methods: A questionnaire describing the organisational structure, the registration
process, good review and decision-making practices of the MCC was completed by
the author (AK) for the purpose of this study and validated by the Registrar of the MCC.
Similar questionnaires were also completed and validated by Australia’s Therapeutic
Goods Administration (TGA), Canada’s Health Canada, Singapore’s Health Science
Authority (HSA) and Switzerland’s Swissmedic.
Results: A comparison of the MCC regulatory process with the four comparative
agencies indicated that they all have similar requirements and employ a full-review model
although the timelines for the MCC were considerably longer. However, similar quality
measures were implemented by all authorities as part of their good review practices
(GRevP) including prioritising transparency, communication, continuous improvement
initiatives and training.
Conclusion: Comparisons made through this study provided insight into the
areas of the MCC registration process that may be improved and have informed
recommendations to SAHPRA including the implementation of facilitated regulatory
pathways, definition of targets for key milestones in regulatory review and formal
implementation and monitoring of GRevP. In order to build quality into the review
process the application of a standardised template for the clinical assessment of
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medicines such as the Universal Methodology for Benefit-Risk Assessment (UMBRA)
could be considered as well as enhancing transparency and communication through
the application of an electronic management system and the development of publicly
available summaries for the basis of approval.
Keywords: South African regulatory review, Medicine Control Council (MCC), TGA, Health Canada,
Swissmedic, HSA
INTRODUCTION
Efforts toward regulatory harmonisation and convergence
have been evident over the last 20 years which has been
supported through the initiation of both regulatory authorities
and the pharmaceutical industry. The impact of these efforts
has translated into globally standardised technical regulations
and requirements for the quality, efficacy, and safety of
medicines and their improved access by patients (WHO,
2000). While each country has autonomy in the manner
in which it effects its regulatory mandate in line with
national requirements, it is recognised that there is value in
benchmarking regulatory models and sharing best practices
(Mashaki Ceyhan et al., 2018). Comparisons between regulatory
authorities of similar size, regulatory mandates, structures,
resource characteristics and regulatory challenges would be more
beneficial than comparisons between authorities with vastly
different characteristics and competencies (Mashaki Ceyhan
et al., 2018). Regulatory authorities in jurisdictions within
the emerging pharmaceutical markets would benefit from
comparisons with other mature regulatory authorities of similar
size such as Health Canada and the Australia’s Therapeutic Goods
Administration (TGA; Hashan et al., 2016).
The national regulatory authority (NRA) of South Africa is
mandated through the Medicines and Related Substances Act,
1965 (Act 101 of 1965) to ensure the efficient, effective and
ethical assessment and registration of medicines and medical
devices that meet defined standards of quality, safety, efficacy
and performance and to ensure that the process of assessing
and registering medicines and medical devices is transparent,
fair, objective and concluded within an appropriate time frame
(Republic of South Africa, 2017). The drive for the establishment
of a more effective regulatory framework in South Africa has
been evident over the past two decades. In June 2017, the
Medicine and Related Substances Act, 1965 (Act 101 of 1965), was
amended to allow for the transition of the NRA of South Africa,
formerly known as the Medicines Control Council (MCC) to the
South African Health Products Regulatory Authority (SAHPRA).
The transition from MCC to SAHPRA has been described in
full by Keyter et al. (2018).
Abbreviations: CMC, chemistry, manufacturing and control (CMC); CPP,
certificate of pharmaceutical product; CTD, Common Technical Document
(CTD); GMP, good manufacturing practice; GRevPs, good review practices; HSA,
(Singapore’s) Health Sciences Authority; MCC, Medicines Control Council; MLE,
major line extension; NASs, new active substances; NRA, national regulatory
authority; PIC/S Pharmaceutical Inspection Co-operation Scheme; SAHPRA,
South African Health Products Authority; TGA, (Australia’s) Therapeutic
Goods Administration.
This new era provided an opportunity to study the regulatory
processes applied by the MCC with a view to enhancing the
regulatory review process and the responsiveness of the NRA
as it moves toward effecting its improved regulatory landscape
as SAHPRA. As SAHPRA moves forward with its objective
for regulatory reform, it is important that the authority has
the relevant capabilities and decision-making frameworks in
place to ensure the efficient application of resources with a
view to improving overall approval times and patients’ access
to new medicines (Keyter et al., 2018). The former regulatory
performance of the MCC should serve as a baseline from
which SAHPRA may monitor progress and achievements whilst
benchmarking planned reform against that of other NRAs in
order to identify the strengths and areas for improvement.
A comparative study of the regulatory performance of
the MCC registration process with that of other regulatory
authorities in the developed and emerging markets has not
been previously performed. Therefore, there is a need for
such a study as the South African NRA strives to become
a reference NRA in the African region. Similar studies have
been performed to compare the Turkish Medicines and Medical
Devices Agency (Mashaki Ceyhan et al., 2018), the Saudi Food
and Drug Authority (Hashan et al., 2016) and the Jordan
Food and Drug Administration (Haqaish et al., 2017) with
the regulatory authorities of Australia, Canada and Singapore.
This study aimed to compare the registration process of
the MCC in South Africa with the processes of Australia,
Canada, Singapore and Switzerland in order to identify the
strengths, challenges and areas of improvement within the
regulatory review processes applied by the MCC and to assess
the level of implementation of quality measures, good review
practices (GRevPs), decision-making principles and continuous
improvement initiatives within the MCC operations, as it strives
toward the goals of improved regulatory performance under the
auspices of SAHPRA.
MATERIALS AND METHODS
Study Participants
This study provides a comparison of the registration process
historically administered by South Africa’s NRA, until recently
known as the MCC, against that of four other NRAs. The four
regulatory authorities selected for this study were based on the
size of the agencies and the patient population they served, the
year since established and the nature of the review model (full
assessment) applied. The data for the comparator agencies was
collected in 2014 and subsequently updated in 2017. Thus, the five
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regulatory authorities included in this study were as follows: the
Therapeutic Goods Administration (TGA) of Australia, Health
Canada, the Health Sciences Authority (HSA) of Singapore,
Swissmedic and the MCC of South Africa.
Study Tool and Data Collection Process
The questionnaire used in the study was completed by the
author (AK) and validated by the then Registrar of the MCC
in 2017 to describe the regulatory review system for market
authorisation of new active substances (NASs) as applied by the
MCC and the overall review time of NASs from the date of
application to the date of approval during the period 2015–2017
(Keyter et al., 2018). The questionnaire (McAuslane et al., 2009),
developed to facilitate capturing data pertaining to regulatory
systems in emerging market jurisdictions with respect to their
implementation of GRevP, was used in this study. Data were
collected using a standardised format to allow for appropriate
comparison and analyses of information collected from multiple
regulatory authorities. The questionnaire consists of four parts:
part 1 – structure of the regulatory authority, the resources
available and the review models applied by the authority; part
2 – regulatory review process using a standardised process map
format to allow for ease of comparison; part 3 – indicators
and description of the measures that have been implemented to
build quality into the regulatory review process and decision-
making practices and the implementation of GRevP to ensure
transparent, consistency and timely regulatory review outcomes;
and part 4 – identifies the enablers and barriers to quality decision
making. The completion of the questionnaire and preparation
of the report by the author were validated by the Registrar of
the MCC. Similar questionnaires were completed by the Head of
the licensing (registration) division of TGA, Health Canada, the
HAS, and Swissmedic and the validated country reports that were
prepared to describe the regulatory systems applied in each of
these countries were used to inform the results of this study. The
questionnaire used in this study was designed to allow for simple
comparative analyses of the structure, processes, and practices
of international regulatory authorities (McAuslane et al., 2009;
Mashaki Ceyhan et al., 2018).
Models of Regulatory Review
Regulatory authorities may apply different regulatory pathways
requiring stratified levels of data assessment depending on the
type of medicine under review and the regulatory status of the
medicine in other reference or benchmark jurisdictions. There
are three types of product review assessments used by regulatory
authorities: the verification review (Type I); abridged (Type II);
and full review (Type III) (McAuslane et al., 2009).
Review Assessment Type I – Verification Model
This model avoids duplication of regulatory effort through the
recognition of the regulatory decisions made by one or more
reference or benchmark authorities (McAuslane et al., 2009). This
model is built on the premise that the regulatory authority has
verified the data submitted for compliance with the reference
country(s) authorisation(s).
Review Assessment Type II – Abridged Model
The abridged model makes provision for a truncated review
focused on the evaluation of clinical data (benefit-risk
assessment) as well as country specific requirements related
to quality of the product (e.g., stability) (McAuslane et al., 2009).
In this model it is a prerequisite that the product has been
approved for market authorisation by a reference or benchmark
regulatory authority.
Review Assessment Type III – Full Review Model
The full review model is intended for use by regulatory
authorities that have the necessary resources to perform a full
independent scientific review of NASs applications (McAuslane
et al., 2009). The full review model does not require evidence of
marketing authorisation from any other regulatory authority at
the time of submission.
Ethics Committee Approval
The study protocol received approval from the University of
Hertfordshire Institutional Ethics Committee. Since the study
participants were regulatory authority staff, it did not require the
local Ethics Committee approval.
RESULTS
Comparative Assessment of Regulatory
Review Processes and Milestones
The five regulatory authorities compared in this study have
similar mandates for regulating medicines for human use.
They are responsible for ensuring that harmonised standards
for market authorisation of such products are applied whilst
ensuring timely access to medicines that are safe, effective
and of good quality. Regulatory authorities have demonstrated
autonomy in the manner in which they execute their mandates,
however, differences may be observed within their regulatory
review processes, timelines and the application of GRevPs. The
regulatory review processes applied by the MCC is depicted
in the standardised process map (Figure 1) (Keyter et al.,
2018). The map provides a simple representation of the review
and authorisation of applications for NASs and MLEs that
are approved on the first cycle, but does not include generic
medicines, biosimilars, complementary medicines, veterinary
medicines or medical devices. The map does not describe the
process, in the event that the application was refused.
The MCC conducted a Type III full assessment in the review
of all applications, including NASs, major line extensions (MLEs)
and generics for orthodox, biological, complementary, and
veterinary medicinal products. A full independent assessment
of quality, efficacy and safety data is performed and an
application for market authorisation for NASs and MLEs
may be submitted to the MCC prior to approval by any
other regulatory authority worldwide. The MCC did not
place any reliance on or consider the review performed
by any other NRAs. The TGA, Health Canada, HSA, and
Swissmedic also perform Type III full assessments and a
Certificate of Pharmaceutical Product (CPP) is not required
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FIGURE 1 | Registration process map for South Africa, calendar days.
at the time of submission (Table 1). A Type II abridged
review is employed by the TGA if requested by the sponsor
and if the product has been approved by one or more
reference authorities, by Swissmedic but only for selected
applications, mainly generic medicine applications and by the
HSA only if the product has been approved by one or more
authorities. The HSA also conducts Type I verification review
but only if the product has been approved by two or more
authorities. While Health Canada are planning to implement
this reliance pathway, Swissmedic intends to roll this out by
2019 (Health Canada, 2018).
Data Requirements
The MCC and HSA do not have a formal pre-application
procedure in place, however, Swissmedic offers this in cases of
a priority review, while, for Type III full reviews, the HSA may
require the sponsor to submit a notification of intent to apply
for market authorisation. The TGA and Health Canada have
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TABLE 1 | Models of assessment of the five agencies and extent of the scientific review.
Type of review model South Africa (MCC) Australia Canada Switzerland Singapore
Verification review (type I) x x x x Xa
Abridged review (type II) x Xb x Xc Xd
Full review (type III) X X X Xe X
EXTENT OF SCIENTIFIC REVIEW
1. Chemistry, manufacturing, and control (CMC) data
Extensive assessment X X X X X
2. Nonclinical data
Extensive assessment X X X X Xf
3. Clinical data
Extensive assessment X X X X
ADDITIONAL INFORMATION OBTAINED (WHERE APPROPRIATE)
Other agencies’ internal review reports X X X X x
(Occasionally)
Reports on the internet X X X X X
(Occasionally)
General internet search X X X X X
(Occasionally)
aOnly if the product has been approved by two or more reference agencies. bOnly if requested by the sponsor and if the product has been approved by two or more
reference agencies. cUsed for selected applications, mainly generic applications. dOnly if the product has been approved by one or more reference agencies. eUsed
mainly for applications for NAS. fOnly for biological and biosimilar products.
formalised this process and consider it as an opportunity to
familiarise reviewers with the product, potentially uncover any
major areas of concern early in the registration process, identify
the potential for priority review and provide a platform for the
sponsor to discuss their submission and obtain scientific advice.
The MCC required the full chemistry, manufacturing and
control (CMC) data, nonclinical data and clinical data to be
submitted in the Common Technical Document (CTD) format
to support the application for market authorisation. The other
four comparative regulatory authorities also request full CMC,
nonclinical and clinical datasets and also conduct an extensive
assessment of these datasets for a Type III full review. All five of
the regulatory authorities perform a review of quality, safety and
efficacy data in parallel and pricing negotiations are separate from
the technical review of the data submitted. The primary scientific
review of the data is performed by internal technical staff of the
four comparative regulatory authorities, with the possibility of
seeking advice from contracted external experts on an ad hoc
basis. The quality assessment of NASs and MLEs conducted by
the MCC was performed by both internal technical staff and
external reviewers while the assessment of clinical data for NASs
and MLEs was reviewed by external reviewers only.
Committee structures within the four comparative NRAs are
similar in that the NRAs engage with various expert committees
on an ad hoc basis to support the scientific review process and to
provide scientific advice and expert opinion on selected dossiers.
The committee structure within the MCC was different in that
all assessment reports would be channelled to various scientific
committees for expert opinion and the final regulatory decision
would be taken by the Medicines Control Council.
All five regulatory authorities are members of the
Pharmaceutical Inspection Co-operation Scheme (PIC/S)
(PIC/S, 2018) and have implemented processes to ensure that
evidence of the good manufacturing practice (GMP) status of the
manufacturer is provided during the review process. Sponsors
may submit a copy of the GMP certificate issued by a reference
agency as evidence of a manufacturers GMP status, however,
if the GMP status of the manufacturer cannot be confirmed at
the time of application for market authorisation, the regulatory
authority may conduct a GMP inspection at the manufacturing
site in parallel to the review process.
Target and Approval Times
The MCC review process consisted of application receipt and
validation procedures, queue time for allocation of applications
to reviewers, a scientific review of CMC, nonclinical and
clinical data conducted in parallel, company response and final
authorisation through the regulatory decision taken by the
Council. The milestone timelines for the MCC review procedures
are displayed in Figure 1. A “fast track” status was assigned
to eligible applications in order to expedite the registration of
essential medicines. While the review process was the same for
“fast track” applications, these applications would be prioritised
over existing applications, queued for allocation to reviewers. The
target set for the overall review time of fast track applications
was 250 calendar days. The median approval times for fast
track NAS applications approved in 2015, 2016, and 2017 were
1218, 921, and 609 calendar days, respectively (Keyter et al.,
2018). There was no target time set for the overall review time
of NASs, but the median approval times for NAS marketing
authorisation applications approved in 2015, 2016, and 2017 were
1175, 1641, and 1466 calendar days, respectively (Keyter et al.,
2018). These data demonstrated that the MCC was neither able
to achieve the target timelines set for fast track applications
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nor meet the targets in 2015, 2016, and 2017 for the key
milestones within the regulatory review process (Figure 1). The
data presented by Keyter et al. (2018) represents the overall
approval time based on the date of application and the date of
registration; data that were routinely monitored and measured
for the period 2015–2017. The median overall approval time
does not include or account for sponsor response time and the
time taken to reach the other milestones identified within the
regulatory review process.
In comparison the TGA, Health Canada, the HSA and
Swissmedic have set overall target review times, for standard
full approvals, at 305 calendar days, 355 calendar days, 270
working days and 330 calendar days, respectively. The overall
target review times set by these four regulatory authorities
do include sponsor response time, unlike those for MCC.
During the period 2013–2017, the TGA, Health Canada and
Swissmedic achieved median approval times of 364, 350, and
487 days, respectively (Bujar et al., 2018). In 2017, Health
Canada Swissmedic TGA approved 30, 29, and 24 NASs,
respectively. Despite these numbers varying on an annual basis,
the overall number of NASs approved by these authorities
has increased (Bujar et al., 2018). The number of NAS
approvals between 2008 and 2012 increased by 56% for
TGA, 46% for Health Canada and 41% for Swissmedic when
compared to the number of NASs approved between 2013 and
2017 (Bujar et al., 2018).
Comparative Assessment of Good
Review Practices
This study identified the quality measures that have been
established and implemented by the five regulatory authorities
with a view to comparing the aptitude and culture of the
authorities in the application of these measures in order to ensure
quality, transparency, consistency and continuous improvement
in the regulatory review process.
Quality Measures
The quality measures evaluated in this comparative study are
listed in Table 2. Swissmedic is the only regulatory authority in
this comparative study that has a dedicated quality department
and that has implemented all the listed quality measures. The
MCC and TGA implemented six of the seven measures and
Heath Canada and the HSA have implemented five quality
measures. Only Health Canada and Swissmedic have formally
implemented GRevPs while the other three authorities have
informally implemented GRevPs. All of the five regulatory
authorities occasionally participated in shared and joint reviews.
Transparency and Communication
Improved transparency and communication are common
goals for regulatory authorities worldwide. There are nine
established transparency and communication parameters that
may be implemented by regulatory authorities to enhance
stakeholder relationships (Table 3). The MCC implemented
seven out of the nine parameters. Currently the industry
is unable to track the progress of applications. Although
the MCC documented and communicated the summary of
grounds for regulatory approval with the sponsor, this summary
was not published or made available in the public domain.
The HSA also does not publish the summary basis of
approval or provide feedback to the industry on submitted
dossiers. The TGA implemented all of the nine transparency
and communication parameters while Swissmedic and Health
Canada implemented eight and the HSA six of the nine
measures (Table 3).
Continuous Improvement Initiatives
A comparison was made of the continuous improvement
initiatives that have been implemented by the five regulatory
authorities. Swissmedic implemented all five initiatives, the TGA
and the HSA implemented four, Health Canada implemented
three and the MCC implemented two of the five initiatives
(Table 4). The MCC did not undergo routine external
quality audits and did not perform routine internal quality
audits. Further, reviews of assessors’ feedback were performed
and the MCC carried out an informal review of feedback
from stakeholders.
Training and Education
Various types of training and education such as induction
training, on-the-job training, attendance at internal and external
courses, international workshops and secondments in other
regulatory authorities can contribute to the development of
personnel and the continuous improvement of the regulatory
review process. All five of the regulatory authorities in this
comparative study implemented all eight of the measures for
training and education.
Enablers and Barriers to Good-Quality Decision
Making
This study identified aspects that the MCC considered to
be pivotal enablers in the effectiveness and efficiency of
the MCC review process and decision-making procedures
for NAS applications. These included the eagerness of the
regulatory authority in South Africa to build confidence in
the regulatory system, the minimal staff turnover at the
MCC that contributed toward the retention of institutional
knowledge and the support from scientific committees in the
regulatory review of applications for market authorisation.
The lack of an electronic document management system
and outdated review processes coupled with fixed committee
structures and decision-making processes were deemed to be
barriers in effecting the regulatory mandate of the MCC
in a timely manner. The other four authorities in the
comparative study listed a variety of enablers that contributed
to good decision making, with common themes of regulatory
convergence and harmonisation and the implementation of
GRevPs emerging as top enablers on the list. The barriers
identified by these authorities included frustrations with
incomplete submissions for market authorisation and the need
for appropriate electronic systems to support the review process
and allow for document management and a full integration of
electronic business systems.
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DISCUSSION
Regulatory authorities around the world strive to enhance their
regulatory performance and in doing so ensure timely patients’
access to safe, good quality, effective medicines. A comparison
of the regulatory systems and review processes implemented
by NRAs globally contribute to the understanding of these
challenges and inform solutions through sharing of best practices
and lessons learned. The MCC recognised the importance of
harmonisation and regulatory convergence and was striving to
align itself with the systems and processes implemented by
mature regulatory authorities in an effort to improve regulatory
performance and ensure timely patient access to medicines. This
study aimed to identify the similarities and differences between
the registration processes applied by similar-sized mature
regulatory authorities and those formerly applied by the MCC.
This study demonstrated the strengths in the regulatory review
process of the MCC and the areas that required improvement
providing an evaluation of the regulatory performance of the
MCC review model and reflected the progress by the MCC
in applying GRevP. The TGA, Health Canada, the HSA and
Swissmedic were selected for this study as authorities with similar
regulatory characteristics and review models to allow for an
appropriate comparison. In particular, these four agencies now
have a work-sharing approach, which was another reason for this
being an appropriate selection criteria of comparative agencies.
Over the past decade a number of regulatory authorities
from the emerging markets have been evaluated using the
questionnaire. Therefore, the four regulatory authorities selected
as comparators for this study were based on the size of the
agencies and the patient population they serve, the year since
established and the nature of the review model (full review)
applied. Furthermore, agencies from the emerging economies
such as Tanzania and Kenya were not considered comparable
to MCC because of the size of the agency and the population
they serve, but in particular because South Africa carries out
“full review” which is different to that of the other agencies in
the region. It is also recognised that the FDA and the EMA
are not appropriate agencies with which benchmark MCC. The
reasons include both the size of the agency and the population
they serve, but in particular the resources available (both in
financial terms and the number of reviewers) to such agencies
which in the case of the FDA include 1200 reviewers of whom
220 are statisticians. As regards EMA, being a consortium of 32
countries engaging rapporteur and co-rapporteur in the review
process would constitute totally a different review model to that
of South Africa.
Review Type and Process
The MCC conducted a Type III full assessment for all NAS
applications for market authorisation and such applications
could be submitted to the MCC prior to approval by another
NRA. In line with the other four comparative NRAs, the
GMP status of the manufacturer is confirmed concurrently with
the review process and a CPP is not required at the time
of submission. The MCC participated in regional alignment
initiatives and conducted shared or joint reviews with other
regulatory authorities such as Zambia, Zimbabwe, Namibia, and
Botswana (Regulatory Resources for Africa, 2015). However, no
formal measures were put in place to ensure consistent quality
during shared or joint reviews and participation in this initiative
did not influence the way in which the MCC conducted reviews
in general. A work-sharing programme is a creative way to
maximise resources even when agencies are separated by time
and distance. This was the rationale for the collaboration between
the agencies in Australia, Canada, Switzerland and Singapore
which now have established efficient work-sharing experience
(McAuslane et al., 2017).
Considering the resource constraints that were faced by
the MCC and the large volumes of applications for market
authorisation received; it is beneficial to consider the use of
facilitated registration pathways (FRPs) to expedite regulatory
decisions and to enhance the re-engineered registration process
envisaged by SAHPRA. Primary FRPs are defined as “pathways
TABLE 2 | The quality measures implemented by the five regulatory authorities.
Measure Regulatory authority
South Africa (MCC) Australia Canada Switzerland Singapore
(6/7) (6/7) (6/7) (7/7) (5/7)
Internal quality policy X X X X x
(Informally)
Good review practice system X X X X X
(Informally) (Informally) (Formally) (Formally) (Informally)
Standard operating procedures for guidance of assessors X X X X X
(Informally)
Assessment templates X X X X X
Dedicated quality department x x x X x
Scientific committee/s appointed X X X X X
Shared and joint reviews X X X X X
(Occasionally) (Occasionally) (Occasionally) (Occasionally) (Occasionally)
Informally: A policy/system/procedure is in place but is not formally documented. Formally: A policy/system/procedure is in place and is formally documented.
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TABLE 3 | Transparency and communication parameters in the five agencies.
Measure Regulatory authority
South Africa (MCC) Australia Canada Switzerland Singapore
(7/9) (9/9) (8/9) (9/9) (6/9)
Feedback to industry on submitted dossiers X X X X x
Details of technical staff to contact Xa X X X X
Pre-submission scientific advice to industry Xb X X X X
Official guidelines to assist industry X X X X X
Industry can track progress of applications x X X X X
Publication of summary of grounds on which approval was granted xc X X X x
Approval times Xd X X X X
Advisory committee meeting dates X X x X x
Approval of products X X X X X
aContact details are made available on an ad hoc basis. bMeetings are held with industry on an ad hoc basis. cSummary is available but is currently not published.
dApproval times are not made available to the public.
TABLE 4 | Continuous improvement initiatives in the five regulatory authorities.
Measure Regulatory authority
South Africa
(MCC) Australia Canada Switzerland Singapore
(2/5) (4/5) (3/5) (5/5) (4/5)
External quality
audits
x x x X x
Internal quality
audits
x X X X X
Internal tracking
systems
x X X X X
Reviews of
assessors’
feedback
X X x X X
Reviews of
stakeholders’
feedback
X X X X X
that speed the development, review and approval of a product;
typically implemented by mature NRAs for a first nondependent
review” (Liberti, 2016). Secondary FRP can be used to expedite
regulatory decisions made by NRAs and contribute toward
decreasing median approval times for medicines resulting in
improved patient access to medicines. Secondary FRPs are based
on the reliance or recognition of a prior review and regulatory
decision made by another NRA. In this case, reliance is defined as
the act whereby, in making a regulatory decision, an NRA in one
jurisdiction considers, and in some cases, gives significant weight
to the regulatory decision made by another NRA and recognition
is defined as the routine acceptance of the regulatory decision
made by another NRA (Liberti, 2016).
Applying FRPs that provide a risk-based approach for the
review of applications for market authorisation may help to
conserve limited resources and reduce regulatory burden by
avoiding duplication of regulatory efforts (Alsager et al., 2015).
This would be an advantage when considered in line with
the recommendations of the WHO (Ward, 2014; WHO, 2014)
by embracing regulatory harmonisation/convergence strategies;
engaging in reliance and recognition activities that allow NRAs
in resource-limited settings to consider or accept regulatory
decisions made by other comparable NRAs (McAuslane et al.,
2018). Furthermore, this could enable the application of an
appropriate framework for benefit-risk assessment to enhance
consistency in the clinical assessment of medicines (Leong et al.,
2015) as well as incorporating the principles of GRevP in routine
regulatory undertakings (WHO, 2014).
Approval Times
As stated by Leng et al. (2015), “The MCC had been
under considerable pressure to increase the rate of medicines
registration and was accused of delaying patients’ access to
affordable and essential medicines.” The outcomes of an
investigation into delayed timelines for registration of medicines,
initiated in 2006 by the Minister of Health, noted a lack of skilled
human resources, poor infrastructure and inefficient regulatory
processes as the major barriers affecting timely patient access to
medicines (Green-Thompson, 2008). This demonstrated that the
MCC, while in existence, neither achieved the target timelines
set for the eligible applications of essential medicines that were
assigned “fast track” status nor met the targets in 2015, 2016,
and 2017 for the key milestones within the regulatory review
process. Furthermore, the MCC made use of a manual system
to track applications for market authorisation, but it is hoped
that the imminent implementation of an electronic document
management system by SAHPRA will promote systematic and
formal communication regarding timelines and milestones to
both internal and external stakeholders.
The MCC did not set a target for overall approval time
of NAS applications. In order for SAHPRA to measure and
improve its regulatory performance it is recommended that
targets for overall approval time and key review milestones need
to be identified, codified into policy and guidelines, recorded,
measured and monitored (Keyter et al., 2018). Appropriate
systems and resources now need to be put in place to ensure
that regulatory performance metrics are analysed on a continuous
basis through formal and routine monitoring resulting in
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measuring the key milestones in the regulatory review process
including administrative and technical screening time, queuing
time prior to review and clock stops measuring the time with
sponsors. There is now the potential to improve regulatory
review time through ongoing analysis of the performance
metrics which may inform continuous improvement initiatives
aimed at streamlining and prioritising the progression of
the review process.
Review times may be improved as a result of the more flexible
approach to committee structures that has been implemented
by SAHPRA. Committee structures within SAHPRA have
been revised to allow for more frequent ad hoc consultation
with scientific committees, limited to applications for market
authorisation requiring expert review and recommendation, as
opposed to routinely channelling assessment reports through
the committees for recommendation at 6-weekly intervals.
Nevertheless, operationalisation of the current system may not
produce satisfactory outcomes and therefore a more fundamental
review of the entire agency could still be proved to be of value.
Good Review Practices
The implementation of GRevP provides a mechanism for NRAs
to enhance regulatory performance (World Health Organization
[WHO], 2015a) and previous studies have demonstrated that
regulatory performance indicators such as overall approval
timelines can be enhanced by instituting quality management
systems and GRevP into the regulatory review process (Cone
and McAuslane, 2006). GRevP are a fundamental part of
overall Good Regulatory Practice (GRP) with a focus on
medical product review (World Health Organization [WHO],
2015b). GRevP are defined by the WHO as “documented
best practices for any aspect related to the process, format,
content and management of a medical product review” (World
Health Organization [WHO], 2015b). The application of
GRevP provides a platform for NRAs to “achieve timeliness,
predictability, consistency, transparency, clarity, efficiency and
high quality in both the content and management of reviews”;
with a view to achieve successful review outcomes (World Health
Organization [WHO], 2015b). Many NRAs have implemented
systems to ensure the consistent application of GRevP and
continue to work toward the evaluation and improvement
of such systems.
The five regulatory authorities in this study implemented the
majority of the essential elements of GRevP. The MCC did not
have a dedicated quality department, however, there are plans to
include dedicated quality personnel within the newly established
SAHPRA. While key quality measures had been established and
were evident in the work performed by the MCC, the need to
formalise the quality management system, including the internal
quality policy, GRevP systems, standard operating procedures
and harmonised assessment templates must be prioritised in
order to enhance SAHPRA operations. The establishment of a
codified quality management system within SAHPRA should
be supported by formally introduced continuous improvement
measures such as internal and external quality audits that are
routinely and formally implemented and the initiation of an
electronic document management system.
The MCC had always recognised the importance of
transparency and communication with stakeholders and as
SAHPRA moves forward it is hoped that many of the measures
that contribute toward transparency and communication will
be formally and routinely implemented in an effort to enhance
the consistency, timeliness and predictability of the review
process. The imminent application of an electronic document
management system will allow for improved transparency as
sponsors will be able to track the progress of applications and
overall approval times and the monitoring and measurement of
key milestones in the review process will be readily available.
However, whilst it is generally agreed that there are several
aspects to review practices that are considered important, it is
recognised that the “summary basis of approval” has far greater
impact with respect to the regulatory process transparency than
other relevant aspects (Vawda and Gray, 2017).
The MCC implemented a guideline in 2007 for the evaluation
of benefit-risk assessment of medicines and prepares a summary
basis of approval for each medicine evaluated; both of which
are key steps in the regulatory review process. The clinical
assessment of NASs was conducted by external experts who
prepared assessment reports that were peer reviewed within the
clinical committee structure. Without a standardised template
for the clinical assessment report, informing regulatory decisions
concerning the registration of a NAS relied heavily on the
experience and expertise of such reviewers. SAHPRA may
consider improving the current framework by building quality
into the process and standardising the template used for benefit-
risk assessment. SAHPRA may also consider implementing the
Universal Methodology for Benefit-Risk Assessment (UMBRA)
framework which has been assessed and applied by several
mature NRAs (Walker et al., 2013) as well as NRAs in the
emerging markets (Mashaki Ceyhan et al., 2018). This structured
approach will promote improved consistency and predictability
in the benefit-risk assessment of medicines as the use of
the UMBRA framework “assists decision makers with clearly
defining the decision, agreeing the requisite properties of the
treatments being considered, assessing the trade-offs among
these properties and making defensible and transparent decisions
regarding the registration of the medicine” (Levitan et al., 2014).
Publication of the summary basis of approval is a norm
for many mature NRAs globally and is a tool that can be
used by regulatory authorities to build confidence in the review
process in order to provide assurance regarding safety provisions
(McAuslane et al., 2009). It is recommended that SAHPRA
consider publishing the summary basis for approval, which were
not previously made available in the public domain by the MCC.
However, it is recognised that in order to achieve this outcome a
change in legislation is required.
The data collected for the purpose of this study has
allowed for a valuable comparison of regulatory authorities
with similar regulatory mandates, similar size and similar
resources characteristics. A number of recommendations have
been provided with a view to inform areas of improvement
that may be prioritised to underpin the success of SAHPRA
as it moves toward goals of regulatory reform and enhanced
regulatory performance.
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Recommendations
The comparison of the registration process previously
applied by the MCC with those of similar medium-size
regulatory authorities such as the TGA, Health Canada, the
HAS, and Swissmedic has highlighted key areas for change
and development. The following recommendations may be
considered by SAHPRA in order to improve on the MCC
regulatory review process.
• Defining target timelines for the key milestones in the
regulatory review process and overall approval time
and ensuring the formal and routine monitoring and
measurement of such metrics.
• Formally implementing and maintaining GRevP in
order to build quality into the review process, resulting
in consistent, predictable, transparent and a timely
regulatory review.
• Applying the universal methodology for benefit-risk
assessment to enhance consistency in the clinical review
of medicines and promote defensible and transparent
decision making.
• Implementing facilitated regulatory pathways and applying
a risk-based approach to the regulatory review process in
order to conserve limited resources and avoid duplication
of regulatory efforts.
• Establishing committee structures within the South African
NRA should allow for ad hoc consultation limited to
applications for market authorisation requiring expert
review and recommendation.
• Enhancing transparency and communication through the
development of summaries for the basis of approval that
may be made available in the public domain.
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